Comparative Pharmacology
Head-to-head clinical analysis: PROTAMINE SULFATE versus VALNAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROTAMINE SULFATE versus VALNAC.
PROTAMINE SULFATE vs VALNAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Protamine sulfate is a cationic protein that binds to heparin, an anionic anticoagulant, forming a stable complex that neutralizes heparin's anticoagulant activity. It also has mild anticoagulant properties of its own.
Valproate semisodium (valproic acid derivative) increases GABA levels in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, and modulates voltage-gated sodium channels and T-type calcium channels. The combination (valproate semisodium) dissociates in the gastrointestinal tract to valproic acid and sodium valproate, providing rapid absorption and sustained release.
1 mg IV per 100 units of heparin to be neutralized, administered slowly (not exceeding 5 mg/min) with continuous monitoring. Maximum single dose: 50 mg.
Adults: 650 mg orally twice daily, with a maximum of 1300 mg per day.
None Documented
None Documented
Complex with heparin: 4–5 minutes (free protamine: 7.4 minutes). Clinically, the anticoagulant reversal effect is rapid but may be transient due to heparin rebound.
3-5 hours (healthy adults). In severe renal impairment (CrCl <30 mL/min), half-life extends to 12-24 hours, increasing risk of accumulation and toxicity.
Primarily renal excretion (heparin-protamine complexes are cleared by the reticuloendothelial system; elimination is largely independent of renal function). <5% excreted unchanged in urine.
Primarily renal (90% unchanged drug), with 10% biliary-fecal. In renal impairment, half-life prolongs significantly, requiring dose adjustment.
Category A/B
Category C
Antidote
Antidote